
# SYNTHESIS OF 3-[4-(1-ETHOXYCARBONYL-1-METHYLETHOXY)PHENYL]-5-(3-PYRIDYL)-1, 2, 4-[3-<sup>14</sup>c]OXADIAZOLE (AT-308-<sup>14</sup>c)

Nobuyoshi Hayashi, Tadashi Toga, and Akio Miyake Central Research Division, Takeda Chemical Industries, Ltd., 17-85, Juso-honmachi 2-chome, Yodogawa-ku, Osaka 532, Japan Received January 28, 1977

Ethyl p-chlorophenoxyisobutyrate<sup>(1,2)</sup> is hypocholesterolemic in rats maintained on normal diets and the other hypocholesterolemic agents have also been introduced into clinical use. From the studies (3-5) of the relationship between structure and activity of 1,2,4-oxadiazole derivatives, 3-[4-(1-ethoxycarbonyl-1-methyl $ethoxy)phenyl]-5-(3-pyridyl)-1,2,4-oxadiazole (AT-308)^{(6,7)} was$ found to be one of the most potent hypocholesterolemic agent in both normocholesterolemic and hypercholesterolemic rats. The carbon-14 labelled compound of AT-308 was desired for the study of metabolic fate in animals, and the labelled position at 3 in 1,2,-4-oxadiazole ring was chosen from the economical point of view. According to the procedure of Harris<sup>(8)</sup> and Barber<sup>(9)</sup>, p-hydroxybenzo-[ $^{14}C$ ]nitrile (III) was synthesized from p-bromophenol and cuprous  $[1^{4}C]$  cyanide (II) which prepared by reacting  $K^{14}CN$  with  $CuSO_4$  in the presence of NaHSO<sub>3</sub> as shown in the reaction scheme. p-Hydroxy-[amidoxime $-^{14}$ C]benzamidoxime (IV) obtained in 81% yield from III was reacted with nicotinoyl chloride to afford 3-(4hydroxyphenyl)-5-(3-pyridyl)-1,2,4- $[3-^{14}C]$ oxadiazole (V) in an excellent yield. Condensation of V with ethyl 2-bromoisobutyrate gave 3-[4-(1-ethoxycarbonyl-1-methylethoxy)phenyl]-5-(3-pyridyl)-1,2,4-[3- $^{14}$ C]oxadiazole (VI) with a specific activity of 3.9

0362-4803/78/0214-0185\$01.00/0 ©1978 by John Wiley & Sons Ltd. mCi/mmole in 13% radiochemical yield based on I. The radiochemical purity of VI was determined by both reverse isotope dilution and radiochromatographic methods, and found to be greater than 99%.



#### EXPERIMENTAL

Potassium  $\begin{bmatrix} 14\\ C \end{bmatrix}$  cyanide (I)

 ${\rm K}^{14}{\rm CN}$  purchased from The Radiochemical Centre, Amersham, England, was diluted to 31 mCi/8 mmole with unlabelled KCN. Cuprous [<sup>14</sup>C]cyanide (II)

A solution of 1860 mg of  $\text{CusO}_4$  in 6 ml of water was kept at  $60^\circ$  in a water bath. Into this copper solution, 520 mg of  $\text{NaHSO}_3$  in 1.5 ml of water was added with stirring over a 1-2 min period, followed immediately by a solution of 520 mg (31 mCi/8 mmole) of

 $K^{14}CN$  in 1.5 ml of water. After 10 min, the hot mixture was filtered and the product was washed with boiling water, then with alcohol. It was dried over  $P_2O_5$  in a vacuum desiccator for 24 h; yield, 610 mg of fine powder in 85%.

## p-Hydroxybenzo-[<sup>14</sup>C]nitrile (III)

A mixture of 610 mg of II and 990 mg of p-bromophenol in 1.6 ml of dimethyl formamide was heated at 150-160° for 4 h and then concentrated to dryness in vacuo. To the residue was added 11.6 ml of 6N HC1 and stirring for 30 min. A solution of 2.3 mg of FeCl<sub>3</sub>.  $6H_20$  in 3 ml of water was added to the acidic solution of the residue, and further stirring for 30 min at 85°. After the resulting mixture was extracted with ether, the extract was washed with water, decolorized with animal charcoal, dried over anhydrous  $Na_2SO_4$  and evaporated. The residue was dissolved in a small amount of  $CH_2Cl_2$  and allowing to stand in a refrigerator. The crystalline product was filtered off, washed with benzene and dried to give 360 mg of III in 44% yield based on II.

## <u>p-Hydroxy-[amidoxime-<sup>14</sup>C]benzamidoxime (IV)</u>

Into a solution of 245 mg of  $Na_2CO_3$  in 1.5 ml of water was dissolved 320 mg of hydroxylamine hydrochloride. The solution was added to 360 mg of III in 1 ml of ethanol and the mixture was heated at 65-70° for 5 h with stirring. After the reaction mixture was kept in a refrigerator over-night, the crystalline product was filtered off, washed with water and dried to give 372 mg of IV in 81% yield based on III.

### 3-(4-Hydroxyphenyl)-5-(3-pyridyl)-1,2,4-[3-14C]oxadiazole(V)

A mixture of 372 mg of IV in 15 ml of pyridine and 530 mg of nicotinoyl chloride hydrochloride was stirred for 30 min at room temperature and then heated at  $110^{\circ}$  for 3 h. After removal of pyridine in vacuo, the residue was crystallized by the addition of 3 ml of water. The product was filtered, washed with cold water and dried to give 560 mg of V in 95.7% yield based on IV. 187

# <u>3-[4-(1-Ethoxycarbonyl-1-methylethoxy)phenyl]-5-)3-pyridyl)-1,2,4-</u> [3-<sup>14</sup>C]oxadiazole (VI)

A mixture of 840 mg of  $K_2CO_3$ , 140 mg of KI and 1.12 ml of ethyl 2-bromoisobutyrate was added to 560 mg of V in 8.4 ml of dimethyl formamide. The reaction mixture was heated at 70-80° for 15 h with stirring and then poured into 60 ml of water. The resulting mixture was extracted with ethyl acetate, and the extract was washed with water, dried over anhydrous  $Na_2SO_4$  and concentrated in vacuo. The residue was chromatographed over 60 g of silica gel using benzene, followed by a mixture of acetone and benzene (1:19, v/v) as the eluents. Evaporation of the fraction of VI left a residue which was recrystallized from ethanol. VI with a specific activity of 3.9 mCi/mmole was obtained in 13% radiochemical yield based on I. Thin-layer radiochromatography of VI

The thin-layer chromatograms (t.l.c) used were 200 mm plate precoated with silica gel and developed with the following three systems:

- (a) silica gel-f (Tokyokasei, Ltd.). Developing solvent, AcOEt and benzene (1:1, v/v): Rf. 0.63.
- (b) silica gel F-254/366 (Woelm). Developing solvent, AcOEt and benzene (1:1, v/v): Rf. 0.54.
- (c) silica gel F-254/366 (Woelm). Developing solvent, CHCl<sub>3</sub> and AcOEt (1:1, v/v): Rf. 0.63.

#### REFERENCES

- 1. Thorp, J.M. and Waring, W.S. Nature <u>194</u>: 948 (1962)
- Avoy, D.R., Swyryd, E.A. and Gould, R.G. J. Lipid Res. <u>6</u>, 369 (1965)
- 3. Imai, Y. and Shimamoto, K. Atherosclerosis 17, 121 (1973)
- Imai, Y., Matsumura, H., Tamura, S. and Shimamoto, K. Atherosclerosis <u>17</u>, 131 (1973)

- Imai, Y., Matsumura, H., Kanamaru, K. and Shimamoto, K. J. Takeda Res. Lab. <u>32</u>, 45 (1973)
- Yurugi, S., Miyake, A., Fushimi, T., Imamiya, E., Matsumura, H. and Imai, Y. - Chem. Pharm. Bull. (Tokyo) <u>21</u>, 1641 (1973)
- 7. Yurugi, S., Miyake, A., Tomimoto, M., Matsumura, H. and Imai, Y.
  Chem. Pharm. Bull. (Tokyo) <u>21</u>, 1885 (1973)
- 8. Harris, H.E. and Herzog, H.L. C.A. <u>65</u>, 13622f (1966)
- 9. Barber, H.J. J. Chem. Soc. <u>1943</u>, 79